Health Care/Hospital
Alpha Global partners with LIO to redefine Mental Health Care in Australia
New platform boosts patient experience and safety, reduces clinician burden, and unlocks operational insight across inpatient mental health hospitals SYDNEY, Aug. 14, 2025 /PRNewswire/ -- Alpha Global, a trusted provider of technology-driven solutions for healthcare and care providers inAustralia...
2025-08-14 11:00
2211
BioDlink Accelerates Global Expansion with Bevacizumab Launch in Colombia and Pakistan
- BioDlink's bevacizumab injection secures marketing authorization in Colombia andPakistan following its recent approval in Nigeria, marking key regulatory milestones in high-need emerging markets. - GMP certification in Brazil, Colombia, and Argentina spans the top three most populous countries...
2025-08-13 20:00
1764
Daewoong Therapeutics Microneedle Patch Achieves Best-in-Class Bioavailability, Proving the Strength of Its Drug-Delivery Platform
* More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new global benchmark * A potential game changer that addresses both the pain of injections and the low efficiency of oral form...
2025-08-13 15:36
1480
Second heartbeat
BEIJING, Aug. 12, 2025 /PRNewswire/ -- A news report from chinadaily.com.cn In this documentary, three patients suffered from advanced heart failure share their stories of howChina's independently-developed non-contact full maglev artificial heart brought hope to their lives. Click to learn more!...
2025-08-13 09:34
2304
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model
- The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy. - ASC47 low dose in combination with tirzepatide demonstrated statistically significantly greater incre...
2025-08-13 07:00
1626
VivaVision Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology
WENZHOU, China, Aug. 12, 2025 /PRNewswire/ -- Recently, VivaVision Biotech ( Zhejiang) Co., Ltd. (VivaVision) announced the appointment of Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS to its Scientific Advisory Board. Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, is currently a professor of oph...
2025-08-13 00:00
1760
Mabwell Announces First Patient Dosed in the US Clinical Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated with ADCs
SHANGHAI, Aug. 12, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced the first patient dosing in the U.S. for a clinical study of its novel nectin-4-targeting antibody-drug conjugate (Bulumtatug Fuvedotin, or BFv, R&D code: 9MW...
2025-08-12 22:00
1763
Aquedeon Medical Inc. Receives FDA Approval to Expand Clinical Trial of Duett Vascular Graft System
CAUTION: Investigational device. Limited by Federal (or United States) law to investigational use. SUNNYVALE, Calif., Aug. 12, 2025 /PRNewswire/ -- Aquedeon Medical Inc. (AMI) is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved the expansion of its Investigationa...
2025-08-12 20:00
1361
Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million
SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- On August 11, Fosun Pharma (SSE:600196, HKEX: 02196) announced that its subsidiary Fosun Pharma Industrial has signed a License Agreement withExpedition Therapeutics Inc.(Expedition) to grant Expedition the rights to develop, manufacture, and commercialize ...
2025-08-12 09:36
1450
AGEBOX Presents iKids-Growth: Pioneering Safe and Natural Support for Children's Height Development
RICHMOND, VA., Aug. 11, 2025 /PRNewswire/ -- In the field of pediatric development, a significant advancement is taking shape. For years, parents have navigated a marketplace of nutritional aids—from basic multivitamins to protein powders—with little more than hope to guide them. iKids-Growth mar...
2025-08-11 21:30
1491
AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a New Era in Fat-Reduction Injectable drugs
— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling — Phase 3 clinical trial underway in South Korea, following strong safety and efficacy results in earlier studies — AMI Pharm positions itself for global expansion in the multi-billion-dollar ...
2025-08-11 20:00
1623
Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy
HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody deve...
2025-08-11 10:52
1385
Hugel launches botulinum toxin Letybo in Malaysia
- The company strengthens brand experience for local medical professionals through academic events and hands-on workshops - It will solidify the market position of premium toxin products through Malaysian partner Venusys Medical SEOUL, South Korea, Aug. 10, 2025 /PRNewswire/ -- Hugel Inc., a lea...
2025-08-11 08:30
1616
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 8, 2025 /PRNewswire/ -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has a...
2025-08-09 09:30
2773
GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology
PISCATAWAY, N.J., Aug. 8, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global leader in life sciences innovation, today unveiled its new global brand platform: Scripting Possibilities—a future-forward identity designed to match the speed, complexity, and promise of modern biote...
2025-08-08 20:30
2632
WuXi XDC Included in MSCI China All Share Index
SHANGHAI, Aug. 8, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced its inclusion in the MSCI China All Share Index, which unders...
2025-08-08 17:32
1632
Minghui Pharmaceutical Announces USD 131 Million Pre-IPO Financing to Advance Late-Stage Pipeline and Global Expansion
SHANGHAI, Aug. 7, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced the closing of a USD 131 million Pre-IPO financing led by new investors OrbiMed and co-led by Qiming Venture Partners. Further support came from existing inve...
2025-08-07 18:00
2384
US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma
TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that US National Cancer Institute (NCI) sponsors Senhwa's second ...
2025-08-07 14:35
1626
FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)
* Approval of AVTOZMA® (tocilizumab-anoh) intravenous infusion expands label to include treatment of adults and pediatric patients aged 2 years and older with cytokine release syndrome (CRS) [1] * AVTOMZA received FDA approval in January 2025, for multiple inflammatory indications including r...
2025-08-06 20:00
1858
The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
* Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL * Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an objective response rate of 84.2% in heavily pretreated CLL/SLL patients SHANGHAI, Aug. 6, 2025 /P...
2025-08-06 19:02
1540
Week's Top Stories
Most Reposted
Radisson Hotel Group accelerates growth in Indonesia with ANTA Hotel Bali Canggu, a member of Radisson Individuals
[Picked up by 313 media titles]
2025-12-10 10:00
HKSTP Makes Strategic Investment in Singapore Technology Company Vizzio; Forges Innovation Pact to Power Next-Generation AI and Smart City
[Picked up by 306 media titles]
2025-12-09 13:31
ARKANCE to Launch BIMLOGIQ - A New AI-Powered Extension to Its AEC Tech Stack Offering
[Picked up by 293 media titles]
2025-12-11 09:07
BeLive Studios, NewUnivers and ChopChop Systems Sign Memorandum of Understanding at ATF 2025
[Picked up by 288 media titles]
2025-12-08 11:00
2025 Guangzhou Design Week Opens: PHOMI Holdings Leads Tech Innovation in Architectural Aesthetics
[Picked up by 287 media titles]
2025-12-06 10:37
Most Read
Abu Dhabi signs agreements and explores opportunities to strengthen partnerships with India and Singapore
2025-12-06 09:00
4825
PAVS Achieves 18,037% YoY Revenue Increase in 2025 Interim Results
2025-12-05 21:45
4038
MALAYSIA REMAINS COMMITTED TO ACCELERATE TRANSFORMATIVE SOLUTIONS FOR A SUSTAINABLE AND INCLUSIVE FUTURE
2025-12-06 00:41
3928
Taipei City's Global Pass: A New Partner Channel for Global Startup Spaces
2025-12-06 01:06
3855
